Zacks Research Upgrades Nephros (NASDAQ:NEPH) to “Hold”

Nephros (NASDAQ:NEPH) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research report issued on Monday,Zacks.com reports.

Several other equities analysts also recently weighed in on NEPH. Northland Securities began coverage on Nephros in a research report on Friday, July 17th. They set a “market perform” rating and a $4.00 target price on the stock. Weiss Ratings lowered shares of Nephros from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday. One investment analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $5.00.

Nephros Trading Down 2.4%

NEPH opened at $3.59 on Monday. The stock has a 50-day moving average of $3.47 and a 200 day moving average of $3.63. Nephros has a 12 month low of $2.66 and a 12 month high of $6.42. The firm has a market cap of $38.98 million, a P/E ratio of 51.29 and a beta of 1.49.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01. The business had revenue of $5.21 million for the quarter, compared to the consensus estimate of $5.02 million. Nephros had a return on equity of 7.66% and a net margin of 4.06%. On average, research analysts forecast that Nephros will post 0.03 earnings per share for the current fiscal year.

Institutional Trading of Nephros

Institutional investors and hedge funds have recently made changes to their positions in the business. Kestra Advisory Services LLC purchased a new stake in shares of Nephros during the fourth quarter valued at $29,000. Dimensional Fund Advisors LP lifted its holdings in Nephros by 52.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company’s stock valued at $62,000 after buying an additional 7,144 shares in the last quarter. Heron Bay Capital Management purchased a new stake in Nephros in the 4th quarter valued at about $66,000. Citadel Advisors LLC grew its stake in Nephros by 39.2% in the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after acquiring an additional 4,655 shares in the last quarter. Finally, XTX Topco Ltd increased its position in shares of Nephros by 48.5% during the fourth quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock worth $105,000 after acquiring an additional 7,062 shares during the period. 41.10% of the stock is currently owned by institutional investors.

Nephros News Roundup

Here are the key news stories impacting Nephros this week:

• Neutral Sentiment: Northland Securities reiterated a “Market Perform” rating on Nephros and set a $4.00 price target, which is only modestly above the recent trading range and suggests limited near-term upside. Nephros analyst estimates and rating update
• Neutral Sentiment: The firm’s updated earnings estimates point to gradual improvement, with Northland forecasting roughly $0.03 EPS for FY2026 and $0.19 EPS for FY2027, plus quarterly EPS in the low cents range through 2027. That outlook is constructive, but not strong enough to trigger a clear bullish re-rating on its own. Nephros earnings estimates update
• Neutral Sentiment: Nephros also announced it will participate in Maxim Group’s “Health, Wellness & Longevity” Virtual Conference on July 22. Conference participation can increase visibility, but it does not by itself change fundamentals. Nephros conference announcement

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.